US · GRAIN MILL PRODUCTS
Tanke Biosciences Corp. TNBI
4 fiscal years on record · USD · FY2012 reported
SEC FILINGS ONLY
Revenue · FY2012
$28.6M
▲ 19.8% vs FY2011
EPS · FY12
$-0.02
Dividend / sh · FY12
—
Payout · FY12
—
ROE · FY12
-1.3%
Net margin · FY12
-0.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 28.6M
Revenue, FY2012 · full 4-year series below
Revenue
Net income
The company lost 1 cents on every revenue dollar this year.
Per share
USD -0.02
Diluted EPS, FY2012
EPS
The company pays no cash dividend.
Profitability
-1.3%
Return on equity, FY2012
ROE
Operating margin15.9%
Net margin-0.7%
Return on assets-0.8%
Each USD of equity lost 1 cents this year.
Returned to shareholders
—
returned in FY2012 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2012
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 28.8M
total assets, end of FY2012
Total assetsUSD 28.8M
EquityUSD 15.8M
CashUSD 6.2M
Gross debtUSD 2.1M
Net debtUSD -4.1M
Current ratio1.85×
The company holds more cash than debt.
History
4 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
·
Operating income $B
0.0
0.0
0.0
·
EBITDA $B
0.0
0.0
0.0
·
Income tax $B
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
0.0
0.0
EPS, diluted $
−0.02
−0.24
0.34
·
Dividend / sh $
·
·
·
·
Payout %
·
·
·
·
ROE %
−1.3
−26.1
33.5
·
Shares out B
0.01
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
12 of 12
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed